MELISSA KALENSKY: Open Payments
NPI 1154681591 · CHICAGO, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,529 in 81 payments from 17 companies in 2025. Trend: 2023 $959 · 2024 $869 · 2025 $1,529
Food & beverage: $1,529
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $233 |
| E.R. Squibb & Sons, L.L.C. | 11 | $207 |
| Lundbeck LLC | 7 | $173 |
| Neurocrine BioSciences, Inc. | 6 | $162 |
| Vanda Pharmaceuticals Inc. | 12 | $156 |
| Otsuka America Pharmaceutical, Inc. | 4 | $123 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $100 |
| Janssen Pharmaceuticals, Inc | 3 | $96 |
| Axsome Therapeutics, Inc. | 2 | $44 |
| Supernus Pharmaceuticals, Inc. | 2 | $41 |
Products named: REXULTI, VRAYLAR, INGREZZA, FANAPT, COBENFY, CAPLYTA, INVEGA SUSTENNA, ABILIFY ASIMTUFII.
Industry payments across IL — which companies pay providers there.
